BACKGROUND: The development of fulminant Clostridium difficile colitis (FCDC) requires prompt operative intervention and is associated with a high mortality rate. The aim of this study was to use a case-control design to define the clinical and laboratory parameters that predict which patients with Clostridium difficile infection are most likely to progress to FCDC. METHODS: Cases from 1994 to 2006 with documented in-hospital progression of Clostridium difficile infection to FCDC were matched retrospectively at the start of medical therapy by age, sex, and intensive care unit (ICU) status to controls with Clostridium difficile infection who did not develop FCDC. Chi-Square and multivariable logistic regression were used to identify risk factors for progression to FCDC. RESULTS: A total of 35 patients with FCDC were matched to 70 controls with Clostridium difficile infection who did not develop FCDC. The patients with FCDC underwent colectomy after an average of 4.6 days of medical therapy and had a mortality rate of 40%. On multivariate analysis, independent risk factors for the development of FCDC were a WBC > 16,000 cells/mm(3) (P < .01) at initiation of therapy, operative therapy within the last 30 days (P = .03), a history of inflammatory bowel disease (P = .04), and a history of intravenous immunoglobulin treatment (P < .01). CONCLUSIONS: Leukocytosis, recent prior operative therapy, and a history of inflammatory bowel disease and intravenous immunoglobulin treatment were negative prognostic indicators for patients with Clostridium difficile infection. The presence of these factors merits close observation for progression to FCDC and acceleration of the planning process for operative intervention.
BACKGROUND: The development of fulminant Clostridium difficilecolitis (FCDC) requires prompt operative intervention and is associated with a high mortality rate. The aim of this study was to use a case-control design to define the clinical and laboratory parameters that predict which patients with Clostridium difficileinfection are most likely to progress to FCDC. METHODS: Cases from 1994 to 2006 with documented in-hospital progression of Clostridium difficileinfection to FCDC were matched retrospectively at the start of medical therapy by age, sex, and intensive care unit (ICU) status to controls with Clostridium difficileinfection who did not develop FCDC. Chi-Square and multivariable logistic regression were used to identify risk factors for progression to FCDC. RESULTS: A total of 35 patients with FCDC were matched to 70 controls with Clostridium difficileinfection who did not develop FCDC. The patients with FCDC underwent colectomy after an average of 4.6 days of medical therapy and had a mortality rate of 40%. On multivariate analysis, independent risk factors for the development of FCDC were a WBC > 16,000 cells/mm(3) (P < .01) at initiation of therapy, operative therapy within the last 30 days (P = .03), a history of inflammatory bowel disease (P = .04), and a history of intravenous immunoglobulin treatment (P < .01). CONCLUSIONS:Leukocytosis, recent prior operative therapy, and a history of inflammatory bowel disease and intravenous immunoglobulin treatment were negative prognostic indicators for patients with Clostridium difficileinfection. The presence of these factors merits close observation for progression to FCDC and acceleration of the planning process for operative intervention.
Authors: Paula Ferrada; Rachael Callcut; Martin D Zielinski; Brandon Bruns; Daniel Dante Yeh; Tanya L Zakrison; Jonathan P Meizoso; Babak Sarani; Richard D Catalano; Peter Kim; Valerie Plant; Amelia Pasley; Linda A Dultz; Asad J Choudhry; Elliott R Haut Journal: J Trauma Acute Care Surg Date: 2017-07 Impact factor: 3.313
Authors: Young Kyung Yoon; Min Ja Kim; Jang Wook Sohn; Hye Suk Kim; Yoon Ji Choi; Jung Sun Kim; Seung Tae Kim; Kyong Hwa Park; Seok Jin Kim; Byung Soo Kim; Sang Won Shin; Yeul Hong Kim; Yong Park Journal: Support Care Cancer Date: 2014-03-05 Impact factor: 3.603
Authors: Aaron T Miller; Parissa Tabrizian; Alexander J Greenstein; Andrew Dikman; John Byrn; Celia Divino Journal: J Gastrointest Surg Date: 2009-02-18 Impact factor: 3.452